BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pertuzumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pertuzumab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05323955-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05323955)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Secondary BRain M
 etastases Prevention After Isolated Intracranial Progression on Trastuzuma
 b/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Fac
 tor Receptor 2+ brEast Cancer With the Addition of Tucatinib\nEstimated pr
 imary completion: November 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05323955
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03125928-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT03125928)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Cli
 nical Trial of Atezolizumab With Paclitaxel\, Trastuzumab\, and Pertuzumab
  in Patients With Metastatic HER-2 Positive Breast Cancer\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03125928
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03803553-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT03803553)
DESCRIPTION:Pertuzumab\, phase 3.\nStudy: Identification and Treatment Of M
 icrometastatic Disease in Stage III Colon Cancer\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03803553
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891561-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05891561)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Sho
 rt-course Trastuzumab\, Pertuzumab with Taxanes in the Adjuvant Treatment 
 of Early HER2-positive Breast Cancer\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05891
 561
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108127-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07108127)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: Efficacy and Safety of Trastuzuma
 b Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Ne
 oadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal
  Cancer\nEstimated primary completion: 1 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07108127
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03595592-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT03595592)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Neoadjuvant Treat
 ment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer\n
 Estimated primary completion: 15 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03595592
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245797-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07245797)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: A Phase II\, Mult
 icenter\, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuv
 ant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneou
 s (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated\, HER2+\,
  eBC\nEstimated primary completion: 15 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07245797
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03006172-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 1 readout est. (NCT03006172)
DESCRIPTION:Pertuzumab\, phase 1\, Breast Cancer.\nStudy: To Evaluate the S
 afety\, Tolerability\, and Pharmacokinetics of Inavolisib Single Agent in 
 Participants With Solid Tumors and in Combination With Endocrine and Targe
 ted Therapies in Participants With Breast Cancer\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03006172
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03297606-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT03297606)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: Canadian Profiling and Targeted A
 gent Utilization Trial (CAPTUR)\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0329760
 6
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04329065-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT04329065)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Concurrent WOKVAC
  Vaccination\, Chemotherapy\, and HER2-Targeted Monoclonal Antibody Therap
 y Before Surgery for the Treatment of Patients With Breast Cancer\nEstimat
 ed primary completion: 31 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04329065
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05978648-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05978648)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Trilaciclib in Pa
 tients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemo
 therapy\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05978648
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187752-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pertuzumab: Phase na readout est. (NCT07187752)
DESCRIPTION:Pertuzumab\, phase na\, HER2-Positive Breast Cancer.\nStudy: Id
 entification of HER2-Positive Breast Cancer Molecular Characterization and
  Subtypes\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07187752
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05325632-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05325632)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Stu
 dy of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel\, Tra
 stuzumab & Pertuzumab\nEstimated primary completion: February 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05325632
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04733118-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT04733118)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Chemotherapy-Free
  pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positiv
 e Early Breast Cancer\nEstimated primary completion: March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04733118
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02320435-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270328
DTEND;VALUE=DATE:20270329
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT02320435)
DESCRIPTION:Pertuzumab\, phase 3.\nStudy: A Safety and Efficacy Extension S
 tudy of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a 
 Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial\nEstimated primary c
 ompletion: 28 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02320435
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510465-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT06510465)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Thera
 py With Weekly Utidelone Combined With Cisplatin for Patients With Breast 
 Cancer (NeoURANIA)\nEstimated primary completion: 31 March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06510465
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04588545-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT04588545)
DESCRIPTION:Pertuzumab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: R
 adiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ B
 reast Leptomeningeal Disease\nEstimated primary completion: April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04588545
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04784715-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT04784715)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Trastuzumab Derux
 tecan (T-DXd) With or Without Pertuzumab Versus Taxane\, Trastuzumab and P
 ertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)\nEs
 timated primary completion: 3 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04784715
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05420454-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270611
SUMMARY:Pertuzumab: Phase 4 readout est. (NCT05420454)
DESCRIPTION:Pertuzumab\, phase 4\, Breast Cancer.\nStudy: A Study for the N
 eoadjuvant Treatment of Breast Cancer\nEstimated primary completion: 10 Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05420
 454
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00781612-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT00781612)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: A Safety Extension Study of Trast
 uzumab Emtansine in Participants Previously Treated With Trastuzumab Emtan
 sine Alone or in Combination With Other Anti-Cancer Therapy in One of the 
 Parent Studies\nEstimated primary completion: 30 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT00781612
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05188313-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT05188313)
DESCRIPTION:Pertuzumab\, phase 3.\nStudy: TRAstuzumab and Pertuzumab for HE
 R2+ Resectable Oesophageal Cancer\nEstimated primary completion: July 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05188313
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528898-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07528898)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Neo
 adjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer
 : An Exploratory Clinical Study.\nEstimated primary completion: July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07528898
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05420467-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Pertuzumab: Phase 4 readout est. (NCT05420467)
DESCRIPTION:Pertuzumab\, phase 4\, Breast Cancer.\nStudy: A Study for the A
 djuvant Treatment of Breast Cancer\nEstimated primary completion: 10 July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05420467
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04301375-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT04301375)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Omi
 ssion of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk
  HER2positive Breast Cancer With High HER2 Addiction and a Complete Respon
 se Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)\n
 Estimated primary completion: 15 July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04301375
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03304080-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT03304080)
DESCRIPTION:Pertuzumab\, phase 1/2.\nStudy: Anastrozole\, Palbociclib\, Tra
 stuzumab and Pertuzumab in HR-positive\, HER2-positive Metastatic Breast\n
 Estimated primary completion: 31 July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03304080
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739511-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT07739511)
DESCRIPTION:Pertuzumab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: P
 aclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy
 : A Dose-Finding Study\nEstimated primary completion: 31 July 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07739511
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05020860-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05020860)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Cor
 relation of Clinical Response to Pathologic Response in Patients With Earl
 y Breast Cancer\nEstimated primary completion: August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05020860
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05150691-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT05150691)
DESCRIPTION:Pertuzumab\, phase 1/2.\nStudy: A Phase 1/2a Study of DB-1303/B
 NT323 in Advanced/Metastatic Solid Tumors\nEstimated primary completion: A
 ugust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 150691
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04973319-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT04973319)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Trastuzumab Combi
 ned With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuv
 ant Therapy\nEstimated primary completion: 1 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04973319
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093931-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Pertuzumab: Phase 4 readout est. (NCT07093931)
DESCRIPTION:Pertuzumab\, phase 4\, HER2-Positive Breast Cancer.\nStudy: Eff
 icacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in H
 ER-2 Positive Breast Cancer\nEstimated primary completion: 1 August 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07093931
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05593094-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT05593094)
DESCRIPTION:Pertuzumab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: A
  Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participant
 s With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced S
 olid Tumors\nEstimated primary completion: 31 August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05593094
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716111-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07716111)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: Neoadjuvant SHR-A1811 and SHR-A17
 01 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenoca
 rcinoma\nEstimated primary completion: 31 August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07716111
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: The Drug Rediscovery Protocol (DR
 UP Trial)\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393425-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07393425)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Trast
 uzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07393425
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140393-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT07140393)
DESCRIPTION:Pertuzumab\, phase 1/2.\nStudy: A Study of HRS-4508 in Combinat
 ion With Other Anti-tumor Therapy for Solid Tumor\nEstimated primary compl
 etion: October 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07140393
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04266249-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT04266249)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: CompassHER2-pCR: 
 Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo
  and Targeted Therapy\nEstimated primary completion: 31 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04266249
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07129018-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07129018)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: Trastuzumab Rezetecan Combined Wi
 th Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07129018
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299890-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07299890)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: An Exploratory St
 udy of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exem
 estane as Neoadjuvant Therapy for Triple-Positive Breast Cancer\nEstimated
  primary completion: 1 November 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07299890
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220135-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07220135)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Trial of Neoadjuv
 ant THP vs TCHP for HER2-Amplified/Positive Breast Cancer\nEstimated prima
 ry completion: 14 November 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07220135
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04692831-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pertuzumab: Phase 1 readout est. (NCT04692831)
DESCRIPTION:Pertuzumab\, phase 1\, Breast Cancer.\nStudy: Testing a New Ima
 ging Agent to Identify Cancer\nEstimated primary completion: 30 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04692831
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07695259-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Pertuzumab: Phase 4 readout est. (NCT07695259)
DESCRIPTION:Pertuzumab\, phase 4\, Breast Cancer.\nStudy: Olaparib+Trastuzu
 mab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer\nEstimated prim
 ary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07695259
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102381-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271229
DTEND;VALUE=DATE:20271230
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07102381)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: A P
 hase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy i
 n Participants With HER2-positive Breast Cancer\nEstimated primary complet
 ion: 29 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07102381
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: Targeted Therapy Directed by Gene
 tic Testing in Treating Patients With Advanced Refractory Solid Tumors\, L
 ymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEstimated prim
 ary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: TAPUR: Testing the Use of Food an
 d Drug Administration (FDA) Approved Drugs That Target a Specific Abnormal
 ity in a Tumor Gene in People With Advanced Stage Cancer\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Fud
 an University Shanghai Cancer Center Breast Cancer Precision Platform Seri
 es Study- Neoadjuvant Therapy\nEstimated primary completion: 31 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246317-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07246317)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Evaluation of Neo
 adjuvant Therapy With Trastuzumab\, Pertuzumab\, Docetaxel\, and QL1706 in
  Early or Locally Advanced HER2+ Breast Cancer\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07246317
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07402473-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07402473)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Optimize Neoadjuv
 ant Therapy in HER2-Positive Early-Stage Breast Cancer\nEstimated primary 
 completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07402473
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589972-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pertuzumab: Phase na readout est. (NCT07589972)
DESCRIPTION:Pertuzumab\, phase na\, HER2-Positive Breast Cancer.\nStudy: Ne
 oadjuvant Trastuzumab\, Pertuzumab Plus Metronomic Vinorelbine for Elderly
  HER2-Positive Breast Cancer\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07589972
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771622-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT06771622)
DESCRIPTION:Pertuzumab\, phase 1/2.\nStudy: Safety and Efficacy of HCB101 i
 n Combination With Multiple Agents in Patients With Advanced Solid Tumors\
 nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06771622
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294508-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Pertuzumab: Phase 2/3 readout est. (NCT07294508)
DESCRIPTION:Pertuzumab\, phase 2/3\, Breast Cancer.\nStudy: A Study to Eval
 uate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurr
 ent or Metastatic Breast Cancer\nEstimated primary completion: 15 January 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07294508
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938021-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07938021)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: HLX22 Plus Serplulimab and Trastu
 zumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers\nEstimat
 ed primary completion: 1 March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07938021
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06876714-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280313
DTEND;VALUE=DATE:20280314
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT06876714)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: ShortStop-HER2: 1
 2 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ B
 reast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plu
 s Trastuzumab\nEstimated primary completion: 13 March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06876714
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795424-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07795424)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Cul
 merciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Th
 erapy for HR+/HER2+ Breast Cancer\nEstimated primary completion: 30 March 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07795424
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07377643-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07377643)
DESCRIPTION:Pertuzumab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: IBI
 354 With or Without Pertuzumab Versus Taxane\, Trastuzumab and Pertuzumab 
 in HER2-positive Metastatic Breast Cancer\nEstimated primary completion: 2
 8 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07377643
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616427-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280520
DTEND;VALUE=DATE:20280521
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07616427)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Fovinaciclib Plus
  Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadju
 vant Strategy for HR-Positive/HER2-Positive Early Breast Cancer\nEstimated
  primary completion: 20 May 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07616427
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441890-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT06441890)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: BRE
 -10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer\nEstim
 ated primary completion: June 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06441890
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07857226-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07857226)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Trastuzumab/Pertu
 zumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer\n
 Estimated primary completion: June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07857226
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05296798-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT05296798)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: A Study to Evalua
 te the Efficacy and Safety of Giredestrant in Combination With Phesgo (Per
 tuzumab\, Trastuzumab\, and Hyaluronidase-zzxf) Versus Phesgo in Participa
 nts With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Can
 cer)\nEstimated primary completion: 15 June 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05296798
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07057427-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07057427)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Efficacy of Nab-P
 HP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Canc
 er\nEstimated primary completion: 30 June 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07057427
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797218-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07797218)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: Neoadjuvant Pyrot
 inib-to-pertuzumab in HER2+ eBC\nEstimated primary completion: 30 June 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07797218
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT06145308)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: Precision Treatment of Recurrent/
 Metastatic Salivary Gland Carcinoma Guided by Molecular Typing\nEstimated 
 primary completion: 10 July 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294534-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pertuzumab: Phase 2/3 readout est. (NCT07294534)
DESCRIPTION:Pertuzumab\, phase 2/3\, Breast Cancer.\nStudy: A Phase II/III 
 Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination 
 With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresa
 t Cancer\nEstimated primary completion: 30 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07294534
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407920-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07407920)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Ph2 Study for Opt
 imization of Adjunct Systemic Therapy in HER2+ Patients\, MolecularPCR Tri
 al\nEstimated primary completion: 30 September 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07407920
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610720-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07610720)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Dalpiciclib\, Ant
 i-HER2 Therapy\, and Endocrine Therapy for Hormone-Receptor-Positive\, HER
 2-Positive Metastatic Breast Cancer\nEstimated primary completion: 1 Novem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761
 0720
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891833-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pertuzumab: Phase 2/3 readout est. (NCT06891833)
DESCRIPTION:Pertuzumab\, phase 2/3\, HER2-Positive Breast Cancer.\nStudy: A
  Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplat
 in + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Bre
 ast Cancer\nEstimated primary completion: December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06891833
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340398-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07340398)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant Trast
 uzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel\, Carboplatin\, Trastuz
 umab\, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Ta
 rgeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Ca
 ncer\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07340398
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581795-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07581795)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Stu
 dy of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus
  Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positiv
 e Breast Cancer\nEstimated primary completion: 28 February 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07581795
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04569747-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290323
DTEND;VALUE=DATE:20290324
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT04569747)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: A S
 ingle Arm Phase II Study of ADjuvant Endocrine Therapy\, Pertuzumab\, and 
 Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive\,
  HER2-positive Breast Cancer\nEstimated primary completion: 23 March 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04569747
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04341181-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT04341181)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: ProTarget - A Danish Nationwide C
 linical Trial on Targeted Cancer Treatment Based on Genomic Profiling\nEst
 imated primary completion: 30 April 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04341181
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612215-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT07612215)
DESCRIPTION:Pertuzumab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: E
 lacestrant in Advanced Triple Positive Breast Cancer\nEstimated primary co
 mpletion: May 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 ertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07612215
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06927180-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT06927180)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: SHR-A1811 Plus Pe
 rtuzumab in the Neoadjuvant Treatment of HER2 Positive BC\nEstimated prima
 ry completion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06927180
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527806-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07527806)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Opt
 imization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Brea
 st Cancer Based on HER2-PET/CT Molecular Imaging\nEstimated primary comple
 tion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/per
 tuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07527806
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647263-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07647263)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Tra
 stuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Ea
 rly Breast Cancer\nEstimated primary completion: June 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07647263
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371585-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07371585)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Trastuzumab Derux
 tecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive 
 Toxicity Management\nEstimated primary completion: 1 August 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07371585
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05722886-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pertuzumab: Phase 2/3 readout est. (NCT05722886)
DESCRIPTION:Pertuzumab\, phase 2/3.\nStudy: DETERMINE (Determining Extended
  Therapeutic Indications for Existing Drugs in Rare Molecularly Defined In
 dications Using a National Evaluation Platform Trial) - Master Screening P
 rotocol\nEstimated primary completion: October 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05722886
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786716-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pertuzumab: Phase 2/3 readout est. (NCT05786716)
DESCRIPTION:Pertuzumab\, phase 2/3.\nStudy: DETERMINE Trial Treatment Arm 0
 4: Trastuzumab in Combination With Pertuzumab in Adult\, Paediatric and Te
 enage/Young Adult Patients With Cancers With HER2 Amplification or Activat
 ing Mutations\nEstimated primary completion: October 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05786716
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518173-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07518173)
DESCRIPTION:Pertuzumab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: A S
 tudy of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzuma
 b and Pertuzumab in Patients With First-line HER2-positive Recurrent or Me
 tastatic Breast Cancer\nEstimated primary completion: December 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07518173
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565324-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07565324)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Pha
 se II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy fo
 r Patients With HER2-positive Early Breast Cancer (UC HER Trial)\nEstimate
 d primary completion: 31 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07565324
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772245-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07772245)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Trial of Retifanl
 imab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast C
 ancer\nEstimated primary completion: 31 December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07772245
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05332561-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05332561)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Genomics Guided T
 argeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COG
 NITION-GUIDE)\nEstimated primary completion: March 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05332561
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459673-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07459673)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: HER
 izon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapi
 es and CNS Prophylaxis to Induce Long-Term Remission\nEstimated primary co
 mpletion: 4 March 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07459673
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439693-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT06439693)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: The
  SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Me
 tastatic Breast Cancer\nEstimated primary completion: 30 March 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06439693
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550972-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07550972)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: Neoadjuvant Treatment of Locally 
 Advanced HNSCC With Pertuzumab Combined With Lenvatinib.\nEstimated primar
 y completion: 31 March 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07550972
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683754-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20300704
DTEND;VALUE=DATE:20300705
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07683754)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: T-DXd Based Thera
 py Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER
 2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd\nEstimated pri
 mary completion: 4 July 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07683754
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716046-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07716046)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Ful
 vestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Ad
 vanced Breast Cancer\nEstimated primary completion: 31 August 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07716046
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: I-S
 PY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Brea
 st Cancer\nEstimated primary completion: December 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05883852-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT05883852)
DESCRIPTION:Pertuzumab\, phase 3\, Breast Cancer.\nStudy: EC-THP Versus TCb
 HP in HER2-positive Lymph Node Positive Early Breast Cancer\nEstimated pri
 mary completion: 1 July 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05883852
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748260-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07748260)
DESCRIPTION:Pertuzumab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: De-
 escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early B
 reast\nEstimated primary completion: 1 July 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07748260
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT05159245)
DESCRIPTION:Pertuzumab\, phase 2.\nStudy: The Finnish National Study to Fac
 ilitate Patient Access to Targeted Anti-cancer Drugs\nEstimated primary co
 mpletion: 25 November 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pertuzumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05159245
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679269-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20320323
DTEND;VALUE=DATE:20320324
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT07679269)
DESCRIPTION:Pertuzumab\, phase 2\, Breast Cancer.\nStudy: Roll-Over Study o
 f Alpelisib (BYL719) for Continued Access and Long-Term Safety.\nEstimated
  primary completion: 23 March 2032. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pertuzumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07679269
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578116-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Pertuzumab: Phase 3 readout est. (NCT07578116)
DESCRIPTION:Pertuzumab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: Add
 ing Surgery and Radiation to the Usual Treatment for HER2-Positive Breast 
 Cancer That Had Already Spread at Diagnosis\nEstimated primary completion:
  31 May 2032. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertuzu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07578116
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686394-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20320802
DTEND;VALUE=DATE:20320803
SUMMARY:Pertuzumab: Phase 1/2 readout est. (NCT06686394)
DESCRIPTION:Pertuzumab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: S
 tudy of Patritumab Deruxtecan With Other Anticancer Agents in Participants
  With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically
  Removed (MK-1022-009)\nEstimated primary completion: 2 August 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pertuzumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06686394
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348134-2241@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20340701
DTEND;VALUE=DATE:20340702
SUMMARY:Pertuzumab: Phase 2 readout est. (NCT06348134)
DESCRIPTION:Pertuzumab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Ass
 essing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With
  HER2+ Breast Cancer Before and After Surgery\nEstimated primary completio
 n: 1 July 2034. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pertu
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06348134
URL:https://assetmemo.bio/drug/pertuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
